Compare Gemini Space Station Inc (GEMI) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gemini Space Station Inc vs Neurocrine Biosciences Inc — how do they compare? Gemini Space Station Inc trades at $4.36 (market cap $582.14M), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B). The key difference: Neurocrine Biosciences Inc is far larger — about 25.1× Gemini Space Station Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Gemini Space Station Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gemini Space Station Inc for 14 Days and Neurocrine Biosciences Inc for 23 Days on average.
| GEMI | NBIX | |
|---|---|---|
Market Cap | $582.14M | $14.60B |
Volume | 1,995,802 | 1,075,694 |
Sector | Financials | Health |
52-Week High | $25.41 | $185.50 |
52-Week Low | $3.54 | $123.10 |
Typical Hold Time | 14 Days | 23 Days |
Enterprise Value | $561.16M | $14.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gemini Space Station (GEMI) trades at $4.49, down 3.85% today, with a bearish technical signal despite oversold RSI readings. The company reported Q2 2026 revenue growth of 37% year-over-year but missed earnings expectations with a net loss of -$517 million. Recent news highlights expansion into commission-free stock trading and prediction markets, though the stock faces class action lawsuits alleging securities violations.
The outlook remains challenged by persistent losses and negative cash flow from operations, offset by financing activities. Analyst consensus is mixed with a $5.33 price target (48% upside), but high business execution and regulatory risks warrant caution. The stock's valuation appears stretched given profitability concerns, making it speculative for risk-tolerant investors.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gemini Space Station Inc
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
